Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M-M Samama

Showing results (111-120 of 184) with videos related to

Pageof 19
Sort By:
American Heart Journal|October 20, 1998
Pathobiology of thrombin in acute coronary syndromesR C Becker, E G Bovill, M J Seghatchian, et al.
Thrombosis and Haemostasis|May 6, 2011
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxM Wolzt, M M Samama, S Kapiotis, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activityF Depasse, G T Gerotziafas, J Busson, et al.
International Angiology : a Journal of the International Union of Angiology|May 22, 2004
Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episodeE Ombandza-Moussa, M M Samama, M H Horellou, et al.
Blood|August 1, 1988
Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosisG Nguyen, M H Horellou, E K Kruithof, et al.
Thrombosis and Haemostasis|July 31, 1998
Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparinP Toulon, B Boutière, M H Horellou, et al.
Journal of Thrombosis and Haemostasis : JTH|June 28, 2005
A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistanceL Bodin, M H Horellou, C Flaujac, et al.
Journal of Thrombosis and Haemostasis : JTH|April 28, 2007
Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generationG T Gerotziafas, A D Petropoulou, E Verdy, et al.
Journal of Thrombosis and Haemostasis : JTH|April 28, 2007
Atypical mutations of the prothrombin gene at positions 20,209 and 20,218, and a novel mutation at position 20,219. Report on 10 patientsC Flaujac, J Conard, M H Horellou, et al.
Presse Medicale (Paris, France : 1983)|June 14, 1997
[Multigenic thrombophilia: genetic anomaly of factor II and mutation of factor V Leiden. Study in a French family]J Conard, C Mabileau-Brouzes, M H Horellou, et al.
Pageof 19

Showing results (111-120 of 184) with videos related to

Sort By:
Pageof 19
American Heart Journal|October 20, 1998
Pathobiology of thrombin in acute coronary syndromesR C Becker, E G Bovill, M J Seghatchian, et al.
Thrombosis and Haemostasis|May 6, 2011
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxM Wolzt, M M Samama, S Kapiotis, et al.
Journal of Thrombosis and Haemostasis : JTH|March 6, 2004
Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activityF Depasse, G T Gerotziafas, J Busson, et al.
International Angiology : a Journal of the International Union of Angiology|May 22, 2004
Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episodeE Ombandza-Moussa, M M Samama, M H Horellou, et al.
Blood|August 1, 1988
Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosisG Nguyen, M H Horellou, E K Kruithof, et al.
Thrombosis and Haemostasis|July 31, 1998
Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparinP Toulon, B Boutière, M H Horellou, et al.
Journal of Thrombosis and Haemostasis : JTH|June 28, 2005
A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistanceL Bodin, M H Horellou, C Flaujac, et al.
Journal of Thrombosis and Haemostasis : JTH|April 28, 2007
Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generationG T Gerotziafas, A D Petropoulou, E Verdy, et al.
Journal of Thrombosis and Haemostasis : JTH|April 28, 2007
Atypical mutations of the prothrombin gene at positions 20,209 and 20,218, and a novel mutation at position 20,219. Report on 10 patientsC Flaujac, J Conard, M H Horellou, et al.
Presse Medicale (Paris, France : 1983)|June 14, 1997
[Multigenic thrombophilia: genetic anomaly of factor II and mutation of factor V Leiden. Study in a French family]J Conard, C Mabileau-Brouzes, M H Horellou, et al.
Pageof 19